Detalhe da pesquisa
1.
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.
Front Oncol
; 10: 202, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32211314